TrialHub connects feasibility experts to local advisors with 15+ years of experience in their countries of choice.

BERKHAMSTED, HERTFORDSHIRE, UNITED KINGDOM, December 9, 2020 /EINPresswire.com/ -- TrialHub - a feasibility intelligence platform, developed by FindMeCure Ltd - announced today the release of a new feature that connects clinical research feasibility professionals to local advisors in their countries of choice.

The clinical trial planning platform can now connect feasibility professionals to their local colleagues within hours. The network of country advisors accessible through the platform consists of experts covering all therapeutic areas with 15+ years of experience.

Under complete confidentiality, they can provide insights about the local clinical research and patient recruitment landscape, including contracts, timelines, and investigator fees, as well as protocol feedback. This is a big enhancement for feasibility experts who won’t have to deal with the administrative burden associated with contacting their local colleagues. They can now have their questions answered via a survey or a phone call within hours.

Knowing local specifics, such as investigator fees, actual startup timelines, patient pathways, and their motivators is key to planning a successful trial. TrialHub has built a highway between feasibility experts and the country advisors who can share these insights.


FindMeCure Ltd. is a tech company dedicated to bringing clinical trials closer to patients. The company has been spreading awareness about clinical trials among more than half a million people around the Globe since 2016.

The team’s direct interaction with patients and investigators led to the development of TrialHub, a feasibility intelligence platform, facilitating clinical trials and patient recruitment success by analyzing the local landscape to provide a 360-degree overview for over 70 countries worldwide.

Nelly Katsarova
FindMeCure Ltd
+1 2037476774
email us here
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.